In this article published in the Spring 2015 edition of Public Domain, the ABA Section of Antitrust Law Intellectual Property Committee newsletter, Nicole Callan discusses "product hopping," a practice in which brand manufacturers launch a new version of a successful drug before generic drug companies can enter the market with generic versions.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
